ACP3 and neoplasm: A strength of the approach taken in the current studies is that we have shown MMAE warheads improve radiosensitized immunogenic tumor control irrespective of how MMAE is delivered to tumors (i.e., ADC or ACPP conjugates), suggesting these results are broadly applicable to the growing pharmaceutical pipeline of auristatin armed ADCs and will yield similar therapeutic synergies when integrated with radiotherapy and immunologics.